No significant association between survival (OS and relapse-free survival) and KRAS mutation status was demonstrated.
The importance of p53 activity independent of mutation status has been demonstrated in human melanoma and therapies that increase the activity of this protein have shown promise [ 52- 54].
As regards to the KRAS mutation status, the results demonstrated a significant association of KRAS codon 13 mutation, but not codon 12, with poor prognosis, but this significance was not retained in adjusted analysis.
13 The cost-effectiveness of first-line maintenance erlotinib in patients with metastatic NSCLC and stable disease, including all patients irrespective of EGFR mutation status, has been demonstrated across three countries in the European Union in recent analyses.
While metastases can be genetically divergent from primary tumors [ 8, 9], heterogeneous BRAF mutation status has also been demonstrated between individual circulating melanoma cells [ 10].
A retrospective analysis of DNMT3A mutation status and decitabine response demonstrated a response rate of 75% in a cohort of eight patients, but this needs further validation in larger studies.
While numerous previous smaller studies investigating the significance of TP53 mutation status or p53 immunoreactivity have demonstrated that p53-deficient endometrial carcinomas tend to have a poor survival outcome, these studies in most cases failed to demonstrate a prognostic importance of p53 in multivariate survival analyses (reviewed in Lee et al, 2009).
This study demonstrates that epigenetic patterns are strongly associated with HR status, subtype, and p53 mutation status and may show heterogeneity within tumor subclass.
Since the previous study did not clarify the feasibility of using serum DNA as a practical source for detection of EGFR mutations, in the present study, we sought to demonstrate that EGFR mutation status determined in serum DNA is the same as in actual tumour samples.
In the present study, we demonstrated PCV and EGFR mutation status as independent prognostic factors in untreated advanced lung adenocarcinoma patients.
